权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Shared mechanisms of alcohol use disorder and Anxiety and effects of the endocannabinoid system

酒精使用障碍和焦虑的共同机制以及内源性大麻素系统的影响

基本信息

批准号：
10666395
负责人：
Renee Martin-Willett
金额：
$ 4.25万
依托单位：
UNIVERSITY OF COLORADO
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-01 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10666395
关键词：
Alcohol consumption Alcohol-Related Disorders Anti-Anxiety Agents Anti-Inflammatory Agents Anxiety Anxiety Disorders Behavior Biological Markers Brain Cannabidiol Central Nervous System Characteristics Cognition Development Discrimination Disease Distant Dose Effectiveness Emotional Equity Evidence based treatment Exposure to Extinction Fright Gender Goals Health Services Accessibility Heart Rate Individual Inflammation Inflammatory Memory Minority Health Research Modeling Neurobiology Outcome Participant Patients Peripheral Nervous System Pharmaceutical Preparations Physiological Population Predisposition Process Property Psychopathology Psychopharmacology Receptor Signaling Reporting Research Research Personnel Rewards Risk Sampling Severities Sex Discrimination Stress Substance Use Disorder Symptoms System Testing Tetrahydrocannabinol Time Training Underrepresented Populations alcohol response alcohol use disorder anxiety symptoms anxiety-related disorders cannabinoid receptor comorbidity diagnostic tool endocannabinoid signaling endogenous cannabinoid system endophenotype ethnic minority exogenous cannabinoid experience gender minority learning extinction marijuana use microbiome neurobiological mechanism new therapeutic target novel psychologic racial minority reduce symptoms sexual minority social stigma societal costs stress related disorder therapeutic target

项目摘要

Project Summary Anxiety disorders and alcohol related disorders (ARD) are both physiologically inflammatory and psychologically debilitating illnesses with high individual and societal costs. In addition, the presence of alcohol use related disorder (ARD) can double the odds of having an anxiety-related disorder. Current treatment options for anxiety disorders or ARDs may be effective in alleviating symptoms for one disorder, but may exacerbate symptoms for the other. Available treatments generally do not target their shared neurobiological mechanisms, in turn highlighting the lack of an objective marker of systemic and neurobiological change associated with both conditions, and limiting the effectiveness of unifocal diagnostic tools and therapeutic targets. Furthermore, there are additional challenges for sexual and ethnic minorities with ARDs or anxiety disorders, including increased stigma, problems accessing care, and exposure to discrimination, all of which are sorely understudied. There is a need for new therapeutic targets that are studied more equitably across diverse groups that account for both physiological effects of anxiety symptomology and comorbidity with ARDs. One such potential target may be the endocannabinoid system (ECS) and its relationship with inflammatory processes. Promisingly, exogenous cannabinoids such as cannabidiol (CBD) have been shown to differentially act on inflammatory mechanisms of the ECS, and CBD alone or with THC may also dose-dependently decrease reward response to alcohol, have anxiolytic properties, be assistive to extinction learning, and possibly stimulate neurosteroidogenesis, which is thought to support fear extinction and limit hyperarousal. Thus, this study will investigate the effects of exogenous cannabinoids among anxiety-symptomatic participants on alcohol consumption, subjective anxiety symptoms, and a shared biomarker summary risk score for anxiety and ARDs. Furthermore, given the current underrepresentation of sexual and ethnic minorities in research on anxiety and ARDs, this study will focus on these populations as well as investigate the effects of discrimination-related stress on the same outcomes. The long-term goal of this proposal is to expand upon the applicant’s background in conducting inclusive research among underrepresented groups while building expertise in the neurobiology and psychopharmacology of co-occurring psychological and substance use disorders. The eventual development of an integrated, evidence-based treatment model that is inclusive of equitable and diverse samples and is broadly applicable across patients is a distant, yet wholly worthwhile goal which this project supports.

项目总结

项目成果

期刊论文数量（6）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Daily associations with cannabis use and sleep quality in anxious cannabis users.

焦虑的大麻使用者的日常与大麻使用和睡眠质量的关联。

DOI：
10.1080/15402002.2023.2217969
发表时间：
2024
期刊：
Behavioral sleep medicine
影响因子：
3.1
作者：
Bidwell,LC;Sznitman,SR;Martin-Willett,R;Hitchcock,LH
通讯作者：
Hitchcock,LH

Baseline affective symptomatology moderates acute subjective effects of high potency THC and CBD cannabis concentrates.

基线情感症状学可缓和高效 THC 和 CBD 大麻浓缩物的急性主观影响。

DOI：
10.1037/pha0000667
发表时间：
2023
期刊：
Experimental and clinical psychopharmacology
影响因子：
2.3
作者：
Martin-Willett,Renée;Skrzynski,CarillonJ;Karoly,HollisC;Elmore,JoshuaS;Bidwell,LCinnamon
通讯作者：
Bidwell,LCinnamon

Cannabis Use Patterns and Related Health Outcomes Among Spanish Speakers in the United States and Internationally.

美国和国际上西班牙语使用者的大麻使用模式和相关健康结果。